Anuli Khairatkar

Join Drug Discovery Chief Ray Dogum and an expert panelist group on May 5 at 11am ET for a virtual event on organ-on-chip advances. Learn how MPS platforms enhance efficacy, safety, ADME insights, and de-risk drug development. Registration is free thanks to sponsor Emulate. Systematically reporting both ancestry and sex as standard biological variables may foster more representative and translationally relevant approaches to drug discovery.

By Anuli Khairatkar Cell lines are foundational in early-stage preclinical drug discovery, serving as well-characterized molecular systems for high-throughput screening, target validation, and toxicity testing. They provide consistent, reproducible models to investigate disease mechanisms and evaluate potential therapies before transitioning to more complex models.